🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,413 results for “ACE” Clear

  1. AZD7798 Placebo: 0.9% saline solution for injection, commercially available., AZD7798

    AstraZeneca AB

    Crohn’s Disease and an Ileostomy

    phase 2 small molecule active

    1 trial

  2. AZD8630, AZD8630, AZD8630 Placebo, AZD8630

    AstraZeneca AB

    Asthma in adults who remain uncontrolled despite medium to high dose ICS plus LABA, and who are at risk of exacerbations.

    phase 2 small molecule active

    1 trial

  3. Abatacept

    Ultragenyx UK Limited

    Wegener's Granulomatosis

    phase 2 small molecule completed

    1 trial

  4. Abatacept

    Ultragenyx UK Limited

    Takayasu's Arteritis

    phase 2 small molecule completed

    1 trial

  5. Abatacept s.c.

    The First People's Hospital of Lianyungang

    Abatacept

    phase 2 small molecule active

    1 trial

  6. Abexinostat

    Xynomic Pharmaceuticals

    Non Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  7. Abiprubart

    Kiniksa Pharmaceuticals International, plc

    Sjögrens Disease

    phase 2 small molecule terminated

    1 trial

  8. Abiraterone Acetate

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Prostate Cancer

    phase 2 small molecule active

    1 trial

  9. Abiraterone Acetate

    United Therapeutics Europe Ltd

    Metastatic Castration Resistant Prostate Cancer

    phase 2 small molecule terminated

    1 trial

  10. Abiraterone acetate

    United Therapeutics Europe Ltd

    Prostate Cancer (Adenocarcinoma)

    phase 2 small molecule active

    1 trial

  11. Abraxane, CAAA614A12101, PACLITAXEL ALBUMIN-BOUND, OXALIPLATIN, FLUOROURACIL, AAA614, IRINOTECAN, AAA514, CALCIUM FOLINATE

    Novartis Pharmaceuticals

    Recurrent or metastatic non-small cell lung cancer (NSCLC), Locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC), Metastatic Breast Carcinoma (BC)

    phase 2 small molecule active

    1 trial

  12. Aceclidine+tropicamide combination

    LENZ Therapeutics

    Presbyopia

    phase 2 small molecule completed

    1 trial

  13. Aceneuramic Acid Extended-Release

    Ultragenyx UK Limited

    Hereditary Inclusion Body Myopathy

    phase 2 small molecule terminated

    1 trial

  14. Acetohydroxamic Acid

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Multidrug-Resistant Tuberculosis

    phase 2 small molecule active

    1 trial

  15. Acido Acetilsalicilico Teva Italia 100 mg compresse gastroresistenti, Tora-Dol 30 mg/ml soluzione iniettabile

    Fondazione Telethon ETS

    Patients scheduled for major surgery for oncologic indication

    phase 2 small molecule active

    1 trial

  16. Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.

    BioMarin Pharmaceutical Australia Pty Ltd

    Achondroplasia

    phase 2 small molecule active

    1 trial

  17. Active drug: pimavanserin 17mg (2 strength tablets)

    Acadia Pharmaceuticals B.V.

    Parkinson Disease

    phase 2 small molecule completed

    1 trial

  18. Albuterol DPI 25 mcg/inh

    Amphastar France Pharmaceuticals

    Asthma

    phase 2 small molecule completed

    1 trial

  19. Aleniglipron or Placebo

    Structure Therapeutics

    Obesity, Overweight, or Chronic Weight Management

    phase 2 small molecule active

    2 trials

  20. Alicaforsen

    IONIS PHARMACEUTICALS INC

    Ulcerative Colitis

    phase 2 small molecule completed

    2 trials

  21. Alitretinoin

    LIGAND PHARMACEUTICALS INC

    Sarcoma, Kaposi

    phase 2 small molecule completed

    2 trials

  22. Alkotinib Capsules

    Suzhou Zelgen Biopharmaceuticals Co.,Ltd

    ALK-positive Non-small Cell Lung Cancer

    phase 2 small molecule terminated

    1 trial

  23. Allogeneic Mesenchymal stromal cells derived from adipose tissue thawed and cultured

    Pari Pharma GmbH

    Adults diagnosed with SJS-TEN with at least 10% of body surface area involved

    phase 2 small molecule active

    1 trial

  24. Alxn1920 placebo product, ALXN1920

    Alexion Europe SAS

    Primary Mebranous Nephropathy (PMN)

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources